Zusammenfassung: Angiotensin-II-Rezeptor-Blocker haben in den vergangenen Jahren eine erhebliche pharmako\u00f6konomische Bedeutung erlangt. Es gibt jedoch bisher keinen fundierten Beleg daf\u00fcr, da\u00df sie alleine oder in Kombination mit ACE-Hemmern wirksamer sind als diese. In nahezu allen Studien zu den wichtigsten Indikationen der ACE-Hemmer haben sie sich als gleichwertig erwiesen. Angiotensin-II-Rezeptor-Blocker sind besser vertr\u00e4glich als ACE-Hemmer; das […]<\/p>\n","protected":false},"excerpt":{"rendered":"
Zusammenfassung: Angiotensin-II-Rezeptor-Blocker haben in den vergangenen Jahren eine erhebliche pharmako\u00f6konomische Bedeutung erlangt. Es gibt jedoch bisher keinen fundierten Beleg daf\u00fcr, da\u00df sie alleine oder in Kombination mit ACE-Hemmern wirksamer sind als diese. In nahezu allen Studien zu den wichtigsten Indikationen der ACE-Hemmer haben sie sich als gleichwertig erwiesen. Angiotensin-II-Rezeptor-Blocker sind besser vertr\u00e4glich als ACE-Hemmer; das […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,1733,1732,316,309,312,314,313,315,317,320,311,307,319,310,324,2505,1226,308,1225,2506,155,1626,2507,1636,71,180,325,1627,1228,1628,1227,1643,321,1938,65,1060,2508,2503,1625,1624,2504,306,2501,2502,1224,366],"class_list":["post-989","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angioneurotisches-oedem","tag-angiooedem","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-blutdruck","tag-calm-studie","tag-candesartan","tag-captopril","tag-charm-studie","tag-claim-studie","tag-diabetes-mellitus-typ-2","tag-diabetische-nephropathie","tag-elite-i-und-ii-studie","tag-eprosartan","tag-herzinfarkt","tag-herzinsuffizienz","tag-hypertonie","tag-idnt-studie","tag-irbesartan","tag-irma-studie","tag-life-studie","tag-lisinopril","tag-losartan","tag-mikroalbuminurie","tag-myokardinfarkt","tag-niereninsuffizienz","tag-optimaal-studie","tag-quincke-oedem","tag-renaal-studie","tag-renoprotektion","tag-resolvd-studie","tag-sartane","tag-scope-studie","tag-spice-studie","tag-telmisartan","tag-valsartan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=989"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/989\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}